Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Photoreceptors and Visual Pathways

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...

Accessory Structures of the Eye

Accessory Structures of the Eye

Optical perception, or vision, is an extraordinary sense dependent on converting light signals received via the ocular organs. These organs, known as eyes, are securely positioned within the bony cavities of the skull, called orbits. The orbits serve a dual purpose: a protective shield for the ocular globes and a stable attachment point for the soft ocular tissues. The eye's external protective mechanisms include the eyelids, which are edged with lashes that act as a barrier against foreign...

Focusing of Light in the Eye

Focusing of Light in the Eye

Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Surgical Management of Complicated Chronic Uveitis: A Case Report.

Romanian journal of ophthalmology·2025

Same author

A Case Series of Serious Adverse Events Following Anti-VEGF Intravitreal Injections.

Romanian journal of ophthalmology·2025

Same author

The 79th Annual Meeting of the European Board of Ophthalmology, alongside the UEMS Meeting.

Romanian journal of ophthalmology·2024

Same author

Chromovitrectomy.

Romanian journal of ophthalmology·2018

Same author

Glaucoma after chemical burns and radiation.

Romanian journal of ophthalmology·2018

Same author

Matrix regenerative therapy.

Romanian journal of ophthalmology·2018

Same journal

[Macular serpiginous choroiditis complicated by macular hole].

Oftalmologia (Bucharest, Romania : 1990)·2015

Same journal

[Therapeutic approach in persistent diabetic macular edema].

Oftalmologia (Bucharest, Romania : 1990)·2015

Same journal

[Preliminary results of treatment with aflibercept].

Oftalmologia (Bucharest, Romania : 1990)·2015

Same journal

MANAGEMENT OF DIABETIC RETINOPATHY, PREVALENCE AND CLINICAL CLASSIFICATION.

Oftalmologia (Bucharest, Romania : 1990)·2015

Same journal

[Changes in intraocular pressure depending on posture].

Oftalmologia (Bucharest, Romania : 1990)·2015

Same journal

[Treatment for penetrating wound caused by metallic intraocular foreign body].

Oftalmologia (Bucharest, Romania : 1990)·2015

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

[Ocular surface disfunction in glaucoma].

Cornel Stefan¹, Diana Melinte Dumitrica

¹Spitalul Clinic de Urgenta Militar Central, Bucuresti, Sectia Clinica de Oftalmologie. CSTEFAN58@YAHOO.COM

Oftalmologia (Bucharest, Romania : 1990)

|January 20, 2009

Summary

This summary is machine-generated.

Travoprost and latanoprost treatments for primary open angle glaucoma (POAG) can negatively impact the ocular surface, potentially causing dry eye symptoms. Both medications effectively reduced intraocular pressure (IOP).

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

Related Experiment Videos

Last Updated: Jun 26, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

Area of Science:

Ophthalmology
Ocular Surface Disease
Glaucoma Treatment

Background:

Primary open angle glaucoma (POAG) is a leading cause of irreversible blindness.
Prostaglandin analogs like travoprost and latanoprost are common treatments for lowering intraocular pressure (IOP).
The impact of these medications on ocular surface health requires further investigation.

Purpose of the Study:

To evaluate the effects of travoprost 0.004% and latanoprost 0.005% on the ocular surface in POAG patients.
To assess changes in tear film stability and goblet cell density.
To compare the ocular surface effects of these two prostaglandin analogs.

Main Methods:

A 6-month prospective observational study involving two groups of newly diagnosed POAG patients.
Group I received travoprost 0.004%, and Group II received latanoprost 0.005%.
Ophthalmic examinations included Schirmer 1 test, tear break-up time (BUT) test, and conjunctival cytology for goblet cell density evaluation before and after treatment.

Main Results:

Statistically significant changes were observed in goblet cell density, Schirmer 1 test, and BUT test results post-treatment (p<0.05).
Both travoprost and latanoprost groups showed similar, significant reductions in intraocular pressure (IOP).
Goblet cell density decreased, and tear film stability was compromised in both treatment groups.

Conclusions:

Travoprost 0.004% and latanoprost 0.005% treatments may exert adverse effects on the ocular surface.
These prostaglandin analog treatments can potentially induce or exacerbate dry eye symptoms in POAG patients.
While effective in lowering IOP, careful monitoring for ocular surface changes is recommended during treatment.